-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana Life Sciences Doses First Patient in Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease

路透·12/17/2025 13:45:18

登錄查看新聞詳情